ライフサイエンスコーパス: AstraZeneca

1 coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca).

2 s such as Ad26.COV2.S (Janssen) and ChAdOx1 (AstraZeneca).

3 e first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca).

4 he first COVID-19 vaccine (Oxford University/AstraZeneca).

5 Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca).

6 piperazine compound (referred to as AZ1) by AstraZeneca.

7 ed by an unrestricted educational grant from AstraZeneca.

8 Kowa Research Institute, Amarin, AstraZeneca.

9 an Lebanese Syrian Associated Charities, and AstraZeneca.

10 en the Anti-Wolbachia consortium (A.WOL) and AstraZeneca.

11 Midlands NIHR Clinical Research Network, and AstraZeneca.

12 idland's NIHR Clinical Research Network, and AstraZeneca.

13 idland's NIHR Clinical Research Network, and AstraZeneca.

14 se, Princess Margaret Cancer Foundation, and AstraZeneca.

15 US National Cancer Institute and AstraZeneca.

16 n, Danish Lung Foundation, Velux Foundation, AstraZeneca.

17 a, National Gynecological Cancer Centre, and AstraZeneca.

18 cer Research Foundation, Sanofi Aventis, and AstraZeneca.

19 earch; the SAILS trial was also supported by AstraZeneca.

20 (GNT300755, GNT569213), Sanofi-Aventis, and AstraZeneca.

21 Midlands NIHR Clinical Research Network, and AstraZeneca.

22 earch Council Australia, Sanofi-Aventis, and AstraZeneca.

23 idland's NIHR Clinical Research Network, and AstraZeneca.

24 e early Genetic Toxicology assessment within AstraZeneca.

25 tween doses, and 8% ChAdOx1 nCoV-19 vaccine [AstraZeneca]).

26 ded-release metoprolol succinate (Toprol-XL, AstraZeneca) 200 mg or 50 mg or placebo for 12 months.

27 r 100,000 vaccinations; 176 ChAdOx1 nCoV-19 (AstraZeneca), 21 tozinameran (Pfizer) and one mRNA-1273

28 AstraZeneca and a Dana-Farber Cancer Institute Collabora

29 AstraZeneca and Atrium Health Levine Cancer Institute.

30 PRIMARY FUNDING SOURCE: AstraZeneca and Bristol-Myers Squibb.

31 AstraZeneca as part of an alliance between AstraZeneca and Merck Sharp & Dohme, a subsidiary of Mer

32 Supported by AstraZeneca and Merck Sharp & Dohme.

33 AstraZeneca and Merck Sharp & Dohme, a subsidiary of

34 - and second-dose efficacy (e.g., the Oxford-AstraZeneca and Moderna vaccines), but not for those wit

35 al medicinal chemistry programmes pursued at AstraZeneca and Novartis.

36 Fractional and standard doses of AstraZeneca and Pfizer among CoronaVac-primed or AstraZe

37 ns are more likely to evaluate vector-based (AstraZeneca and Sputnik) or whole-virus vaccines (Sinoph

38 the literature, internal study databases at AstraZeneca and the Medical Research Institute of New Ze

39 AstraZeneca and the UK Department of Health and Social C

40 SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson)

41 NA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary course ranged fro

42 ID-19-positive vaccinated (Covishield/Oxford-AstraZeneca) and non-vaccinated individuals and to compa

43 he ChAdOx1 nCoV-19 Vaxzevria vaccine (Oxford/AstraZeneca) and the JNJ-7836735 Johnson & Johnson vacci

44 NTech), mRNA-1273 (Moderna), ChAdOx1 (Oxford-AstraZeneca), and Ad26.COV2.S (Johnson & Johnson/Janssen

45 sures were doses 1-3 of the Pfizer, Moderna, AstraZeneca, and Janssen COVID-19 vaccines; outcomes wer

46 Cancer Research UK, AstraZeneca, and Puma Biotechnology.

47 mber G1000417/94909), ICON, GlaxoSmithKline, AstraZeneca, and the Medical Evaluation Unit.

48 uth Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome.

49 AstraZeneca as part of an alliance between AstraZeneca a

50 that define humoral responses to the Oxford-AstraZeneca (AZ) and BNT162b2 (Pfizer-BioNTech) vaccines

51 eveal a competitive relationship between the AstraZeneca (AZ) GSMs and the established second generat

52 loyed (total vaccinated = 1,003,960 adults): AstraZeneca (AZ/Covishield), Pfizer/BioNtech, Sinopharm

53 data from England for three vaccines (Oxford/AstraZeneca AZD1222, Pfizer-BioNTech BNT162b2, Moderna m

54 tive Board, Region Vastra Gotaland (Sweden), AstraZeneca, Boehringer Ingelheim (Canada), Pfizer (Cana

55 e COPD Foundation through contributions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepraco

56 e COPD Foundation through contributions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepraco

57 Vac-primed participants following Pfizer and AstraZeneca boosters.

58 nal Institutes of Health, and AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, and Pfizer

59 rch, Heart and Stroke Foundation of Ontario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada)

60 ugh the Mary-Jean Mitchell Green Foundation, AstraZeneca, Cancer Research UK, and the National Instit

61 SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic complication termed

62 city was tested by cell pretreatment with an AstraZeneca CCR3 antagonist (10(-8) - 10(-6) M).

63 Using thirty cell lines' data from the AstraZeneca Cell Bank, we demonstrated that our proposed

64 new cell lines are continually added to the AstraZeneca Cell Bank, we integrated the transfer learni

65 indicates considerable uncertainty in Oxford-AstraZeneca ChAdOx1 and Janssen Ad26.COV2.S VE against a

66 accination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determ

67 62b2 vaccine, 55% after 1 dose of the Oxford-Astrazeneca ChAdOx1 vaccine, and 69% after 2 doses of th

68 dard Pfizer BNT162b2, fractional or standard AstraZeneca ChAdOx1, and standard dose CoronaVac) follow

69 ted with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-

70 162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases

71 A two-dose regimen of the Oxford-AstraZeneca (ChAdOx1) Covid-19 vaccine with an inter-dos

72 ectiveness (VE) for either 2 doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac

73 Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca; ChAdOx1) vaccines against any new SARS-CoV-

74 Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endot

75 [Vir Biotechnology] monotherapy and AZD7442 [AstraZeneca] combination), which correspond to ones used

76 l-vectored ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca), compared with a third homologous dose of C

77 A virtual screen of a subsection of the AstraZeneca compound collection was performed for checkp

78 4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.

79 Whole-cell high-throughput screening of the AstraZeneca compound library against the asexual blood s

80 The AstraZeneca compound selectively inhibited these CCL24-m

81 From the phenotypic screening of the AstraZeneca corporate compound collection, N-aryl-2-amin

82 The excipient of potential concern in the AstraZeneca COVID-19 vaccine is polysorbate 80 (PS80).

83 skin prick testing to PS80 (20%) and to the AstraZeneca COVID-19 vaccine prior to vaccination.

84 eight patients allergic to PEG tolerated the AstraZeneca COVID-19 vaccine, even in 2 patients where t

85 could be vaccinated with the PS80 containing AstraZeneca COVID-19 vaccine.

86 and 1 with a positive skin prick test to the AstraZeneca COVID-19 vaccine.

87 Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) COVID-19 vaccines have shown high efficacy

88 e 80, and the BNT162b2 (Pfizer) and AZD1222 (AstraZeneca) COVID-19 vaccines in patients with a histor

89 varying lipophilicity, in the context of the AstraZeneca data set.

90 of successful PK predictions so that 83% of AstraZeneca drug development projects progress in the cl

91 g Disease, Boehringer Ingelheim New Zealand, AstraZeneca Educational Grant, National Institute for He

92 AstraZeneca, Experimental Cancer Medicine Centre, Prosta

93 Acerta, AstraZeneca, F Hoffmann-La Roche, and AbbVie.

94 ing April 2020 through collaboration between AstraZeneca, GlaxoSmithKline, and the University of Camb

95 Acerta Pharma, a member of the AstraZeneca Group, and R35 CA198183 (to JCB).

96 Acerta Pharma, a member of the AstraZeneca Group.

97 ral vector COVID-19 vaccine ChAdOx1 nCoV-19 (AstraZeneca) has been associated with rare vaccine-induc

98 r AZD7442 (tixagevimab-cilgavimab [Evusheld; AstraZeneca]) has been found effective among immunocompr

99 Businesses such as AstraZeneca have also prioritised voluntary asymptomatic

100 The cases against TAP and AstraZeneca have been followed by federal and state inve

101 denoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA

102 e after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2

103 discuss methods to predict human PK used by AstraZeneca, how these predictions are assessed and what

104 st TAP Pharmaceuticals (Lake Forest, IL) and AstraZeneca International (London, United Kingdom), each

105 (COVID-19) vaccine phase 3 trials (Moderna, AstraZeneca, Janssen, and Novavax) was performed.

106 accine efficacy trials sponsored by Moderna, AstraZeneca, Janssen, and Novavax.

107 In the accompanying paper, a team at AstraZeneca led by Jason G.

108 ere administered the NKB antagonist AZD4901 (AstraZeneca, London, UK) 40 mg orally twice daily for 5

109 o placebo or beta(1)-AR blockade (Toprol-XL, AstraZeneca, London, United Kingdom) for 2 years.

110 , NY) with either gefitinib (Iressa, ZD1839; AstraZeneca, Macclesfield, UK) or erlotinib (Tarceva, OS

111 AstraZeneca; Merck Sharpe & Dohme, a subsidiary of Merck

112 With the temporary suspension of "AstraZeneca", negative associations shifted: Mainstream

113 o observed following booster doses of Oxford-AstraZeneca or BNT162b2 (Pfizer-BioNTech) vaccine.

114 lf-reported likelihood of taking an assigned AstraZeneca or Johnson & Johnson vaccine was higher for

115 ents were randomly assigned a vaccine brand (AstraZeneca or Johnson & Johnson) and information about

116 experiment with random assignment of brand (AstraZeneca or Johnson & Johnson), information about the

117 individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.

118 lowing a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech.

119 and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines.

120 a third dose of either heterologous ChAdOx1 (AstraZeneca) or homologous BNT162b2 (BioNTech) was admin

121 o receive two years of candesartan (Atacand, AstraZeneca) or placebo, followed by two years of placeb

122 CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), or BNT162b2 (Pfizer-BioNTech) vaccine boos

123 BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a

124 nti-PF4) antibodies in individuals following AstraZeneca-Oxford vaccination and named this new syndro

125 ays of vaccination with the ChAdOx1 nCov-19 (AstraZeneca/Oxford) and Ad.26.COV2.S (Janssen/Johnson &

126 opment and licensure of the ChAdOx1 nCoV-19 (AstraZeneca; Oxford University) and Ad26.COV2.S (Janssen

127 %) Novavax participants, 3549/32 380 (11.0%) AstraZeneca participants, and 5047/43 788 (11.5%) Jansse

128 dverse events of COVID-19 Vaccination Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, Johnson and Johns

129 nce between M. D. Anderson Cancer Center and AstraZeneca Pharmaceuticals LP, a concerted effort has b

130 AbbVie Inc., AstraZeneca Pharmaceuticals LP, NIH.

131 US National Cancer Institute and AstraZeneca Pharmaceuticals LP.

132 ement supported by an educational grant from AstraZeneca Pharmaceuticals.

133 US National Cancer Institute, AstraZeneca Pharmaceuticals.

134 dard dose CoronaVac) following CoronaVac and AstraZeneca primary series in healthy adults in Indonesi

135 AstraZeneca-primed participants have lower initial respo

136 aZeneca and Pfizer among CoronaVac-primed or AstraZeneca-primed participants, boost immune responses

137 Cancer Research UK, AstraZeneca, Prostate Cancer UK, the Prostate Cancer Fou

138 ion but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infecti

139 zer/BioNTech BNT162B2, Moderna mRNA-1273 and AstraZeneca recombinant adenoviral ChAdOx1-S.

140 al development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron and Lilly, against SARS-CoV-2 var

141 9, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca, Regeneron, Eli Lilly (LY-CoV555 and LY-CoV0

142 Here we perform a high-throughput screen of AstraZeneca's 1.3 million in-house compound library and

143 oduce Mantis-ML 2.0, a framework integrating AstraZeneca's Biological Insights Knowledge Graph and nu

144 hibitors of a human histone deacetylase from AstraZeneca's collection of 2 million small molecules an

145 A biochemical screen of AstraZeneca's compound library using GlmU of Escherichia

146 Here we report AstraZeneca's large drug combination dataset, consisting

147 Here, we present our method for DREAM AstraZeneca-Sanger Drug Combination Prediction Challenge

148 It is based on the winning algorithm in the AstraZeneca-Sanger Drug Combination Prediction DREAM Cha

149 ncil Australia, Breast Cancer Research Fund, AstraZeneca, Sanofi Aventis.

150 AstraZeneca, Sanofi, Bristol Myers Squibb, SOS Attaque C

151 tario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servi

152 ithin 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine.

153 British Heart Foundation, Pfizer, AstraZeneca, Schering-Plough, National Institute for Hea

154 o tested a previously discovered proprietary AstraZeneca small molecule and correctly determined the

155 of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm.

156 e of Health Research, The Medicines Company, AstraZeneca, The Bentley Drivers Club (UK).

157 This manuscript was supported by AstraZeneca, the manufacturer of benralizumab.

158 al-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-

159 tiftung, Wellcome Trust, Cancer Research UK, AstraZeneca UK, University Hospitals of Leicester, Unive

160 er Research UK, UK Medical Research Council, AstraZeneca UK, US Army, EU-Biomed.

161 g Disease, Boehringer Ingelheim New Zealand, AstraZeneca, UK National Institute for Health Research,

162 hip, National Institute for Health Research, AstraZeneca-University of Manchester Strategic Alliance

163 in Saudi Arabia (Pfizer-BioNTech and Oxford-AstraZeneca) using telemedicine technology.

164 accine (1407 two doses), and 2738 the Oxford-AstraZeneca vaccine (49 two doses).

165 first booster dose (n = 53), and (C) Oxford-AstraZeneca vaccine (n = 29).

166 978 880 first-dose recipients of the Oxford/AstraZeneca vaccine (OR, 0.97; 95% CI, 0.82-1.15; I2 = 0

167 e safely vaccinated with the PS80 containing AstraZeneca vaccine and need only avoid the PEG-containi

168 ination schedules: (A) CoronaVac with Oxford-AstraZeneca vaccine as the first booster dose (n = 46),

169 re more frequent following the first dose of AstraZeneca vaccine compared to Pfizer-BioNTech vaccine,

170 The Oxford-AstraZeneca vaccine significantly increased the risk of

171 The first dose of the Oxford-AstraZeneca vaccine was associated with acute MI and PE

172 The adverse events of the Oxford-AstraZeneca vaccine were linked to 1339 cases of GBS fol

173 f local adverse events (24.8% versus 9.8% in AstraZeneca vaccine).

174 iving the first dose of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine for COVID-19.

175 cine (CoronaVac) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine successfully increased anti-spike a

176 COV2.S (Janssen), or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.

177 r receiving either Pfizer-BioNTech or Oxford-AstraZeneca vaccines during June 2021.

178 04% and 2.09% for Pfizer-BioNTech and Oxford-AstraZeneca vaccines, respectively, with no serious even

179 recipients of the Pfizer/BioNTech vs Oxford/AstraZeneca vaccines.

180 e of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between

181 Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in our initial analyses.

182 ), mRNA-1273 (Moderna Spikevax) and ChAdOx1 (AstraZeneca Vaxzevria) vaccines against symptomatic SARS

183 NA-1273, n=23; Janssen-Ad26.COV2.S, n=9; and AstraZeneca-Vaxzevria, n=8).

184 One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat

185 Moderna)-and 1 viral vector vaccine-AZD1222 (AstraZeneca)-were collected from national vaccination re

186 ceipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector.

187 pivotal phase II trial of gefitinib (Iressa; AstraZeneca, Wilmington, DE) conducted in the United Sta

188 ies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal

189 News titles from alternative sources framed "AstraZeneca" with sadness, absent in mainstream titles.

190 ifted: Mainstream titles prominently linked "AstraZeneca" with side effects, while "Pfizer" underwent